The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 68-77

  Park, J H ^a   McMillan, D C ^a   Horgan, P G ^a   Roxburgh, C S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aspirin; Colorectal cancer; Histamine; Immune response; Inflammation; NSAID; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CELECOXIB; CETUXIMAB; CIMETIDINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PROSTAGLANDIN E2; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; DRUG EFFECT; FAMILIAL COLON POLYPOSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLAMMATORY INFILTRATE; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; METASTASIS POTENTIAL; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OXIDATIVE STRESS; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ASPIRIN; COLORECTAL CANCER; HISTAMINE; IMMUNE RESPONSE; INFLAMMATION; NSAID; STATIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84887121545     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.05.006     Document Type: Review

References (124)

1. UK CR. Bowel cancer statistics: Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality.
2. McArdle C.S., McMillan D.C., Hole D.J. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 2003, 90(6):711-715.
3. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27(19):3109-3116.
4. Ali R., Toh H.C., Chia W.K. The utility of aspirin in dukes C and high risk dukes B colorectal cancer-the ASCOLT study: study protocol for a randomized controlled trial. Trials 2011, 12:261.
5. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
6. Roxburgh C.S.D., McMillan D.C. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012, 38(5):451-466.
7. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6(1):149-163.
8. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6):448-454.
9. Lin C.Y., Bai D.J., Yuan H.Y., Wang K., Yang G.L., Hu M.B., et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. World J Gastroenterol 2004, 10(1):136-142.
10. Ueda T., Shimada E., Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994, 29(4):423-429.
11. Hanna N., Fidler I.J. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980, 65(4):801-809.
12. McMillan D.C., Fyffe G.D., Wotherspoon H.A., Cooke T.G., McArdle C.S. Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer. Dis Colon Rectum 1997, 40(9):1068-1071.
13. Chia W.K., Ali R., Toh H.C. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012, 9(10):561-570.
14. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121(4):241-246.
15. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333(10):609-614.
16. Benedetti A.L., Collet J.P., Boivin J.F., Hanley J.A. Effect of nonsteroidal anti-inflammatory drugs on stage of colon cancer at diagnosis. J Clin Epidemiol 2003, 56(8):782-787.
17. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
18. Flossmann E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369(9573):1603-1613.
19. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376(9754):1741-1750.
20. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53(6):1322-1327.
21. Thun M.J.M., Namboodiri M.M.M., Heath C.W.C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325(23):1593-1596.
22. Zell J.A., Ziogas A., Bernstein L., Clarke C.A., Deapen D., Largent J.A., et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009, 115(24):5662-5671.
23. Coghill A.E., Newcomb P.A., Campbell P.T., Burnett-Hartman A.N., Adams S.V., Poole E.M., et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011, 60(4):491-498.
24. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2007, 146(5):361-364.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
26. Giardiello F.M.F., Hamilton S.R.S., Krush A.J.A., Piantadosi S.S., Hylind L.M.L., Celano P.P., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328(18):1313-1316.
27. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378(9809):2081-2087.
28. Vinogradova Y., Hippisley-Cox J., Coupland C., Logan R.F. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007, 133(2):393-402.
29. Harris R.E., Beebe-Donk J., Alshafie G.A. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008, 8:237.
30. Church R.D., Fleshman J.W., McLeod H.L. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003, 90(9):1055-1067.
31. Cha Y.I., DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007, 58:239-252.
32. Fenwick S.W., Toogood G.J., Lodge J.P., Hull M.A. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003, 125(3):716-729.
33. Chalmers C.R., Wilson D.J., Ward J., Robinson P.J., Toogood G.J., Hull M.A. Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases. Gut 2006, 55(7):1058-1059.
34. Auman J.T., Church R., Lee S.Y., Watson M.A., Fleshman J.W., McLeod H.L. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 2008, 44(12):1754-1760.
35. Lonnroth C., Andersson M., Nordgren S., Lundholm K. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol 2012, 41(1):15-23.
36. Tuynman J.B., Peppelenbosch M.P., Richel D.J. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004, 52(2):81-101.
37. Schror K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 2011, 25(4-5):473-484.
38. Dimberg J., Samuelsson A., Hugander A., Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999, 45(5):730-732.
39. Nasir A., Kaiser H.E., Boulware D., Hakam A., Zhao H., Yeatman T., et al. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer 2004, 3(4):243-247.
40. Gustafsson A., Hansson E., Kressner U., Nordgren S., Andersson M., Wang W., et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 2007, 121(2):232-240.
41. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007, 356(21):2131-2142.
42. Barry E.L., Sansbury L.B., Grau M.V., Ali I.U., Tsang S., Munroe D.J., et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009, 18(10):2726-2733.
43. Krishnan K., Ruffin M.T., Normolle D., Shureiqi I., Burney K., Bailey J., et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001, 10(5):447-453.
44. Thun M.J., Jacobs E.J., Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012, 9(5):259-267.
45. Sciulli M.G., Filabozzi P., Tacconelli S., Padovano R., Ricciotti E., Capone M.L., et al. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 2005, 72(2):79-83.
46. Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747.
47. Boon E.M., Keller J.J., Wormhoudt T.A., Giardiello F.M., Offerhaus G.J., van der Neut R., et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004, 90(1):224-229.
48. Greenspan E.J., Madigan J.P., Boardman L.A., Rosenberg D.W. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) 2011, 4(1):161-171.
49. Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367(17):1596-1606.
50. Seufert B.L., Poole E.M., Whitton J., Xiao L., Makar K.W., Campbell P.T., et al. IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the colon cancer family registry. Carcinogenesis 2013, 34(1):79-85.
51. Solheim T.S., Fearon K.C., Blum D., Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013, 52(1):6-17.
52. Chan A.T., Ogino S., Giovannucci E.L., Fuchs C.S. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011, 140(3):799-808. [quiz e11].
53. Chan A.T., Sima C.S., Zauber A.G., Ridker P.M., Hawk E.T., Bertagnolli M.M. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) 2011, 4(8):1172-1180.
54. Hussain M., Javeed A., Ashraf M., Al-Zaubai N., Stewart A., Mukhtar M.M. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res 2012, 66(1):7-18.
55. Lonnroth C., Andersson M., Arvidsson A., Nordgren S., Brevinge H., Lagerstedt K., et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008, 8:5.
56. Yaqub S., Henjum K., Mahic M., Jahnsen F.L., Aandahl E.M., Bjornbeth B.A., et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008, 57(6):813-821.
57. Han T., Nemoto T., Ledesma E.J., Bruno S. Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients. Int J Immunopharmacol 1983, 5(1):11-15.
58. Balch C.M., Dougherty P.A., Cloud G.A., Tilden A.B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984, 95(1):71-77.
59. Markewitz A., Faist E., Lang S., Endres S., Fuchs D., Reichart B. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J Thorac Cardiovasc Surg 1993, 105(1):15-24.
60. Gogos C.A., Maroulis J., Zoumbos N.C., Salsa B., Kalfarentzos F. Effect of parenteral indomethacin on T-lymphocyte subpopulations and cytokine production in patients under major surgical operations. Res Exp Med (Berlin) 1995, 195(2):85-92.
61. Ho G.Y., Xue X., Cushman M., McKeown-Eyssen G., Sandler R.S., Ahnen D.J., et al. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst 2009, 101(23):1650-1654.
62. Konturek P.C., Rembiasz K., Burnat G., Konturek S.J., Tusinela M., Bielanski W., et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci 2006, 51(4):779-787.
63. McMillan D.C., Leen E., Smith J., Sturgeon C., Preston T., Cooke T.G., et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1995, 21(5):531-534.
64. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302(6):649-658.
65. Bastiaannet E., Sampieri K., Dekkers O.M., de Craen A.J., van Herk-Sukel M.P., Lemmens V., et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012, 106(9):1564-1570.
66. Fuchs C.S., Meyerhardt J.A., Heseltine D.L., Niedzwiecki D., Hollis D., Chan A.T., et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803. J Clin Oncol 2005, 23(16S):3530.
67. Midgley R.S., McConkey C.C., Johnstone E.C., Dunn J.A., Smith J.L., Grumett S.A., et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010, 28(30):4575-4580.
68. Phase III Randomized Study of Adjuvant Celecoxib with Fluorouracil and Leucovorin Calcium in Patients With Curatively Resected Stage III Adenocarcinoma of the Colon National Cancer Institute: National Institutes of Health; 2004 [updated 22/6/2006; cited 2012 October]. Available from: http://cancer.gov/clinicaltrials/search/view?cdrid=367335&version=healthprofessional.
69. Davis T.W., Hunter N., Trifan O.C., Milas L., Masferrer J.L. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003, 26(4):S58-S61.
70. Debucquoy A., Roels S., Goethals L., Libbrecht L., Van Cutsem E., Geboes K., et al. Double blind randomized phase II study with radiation+5-fluorouracil+/- celecoxib for resectable rectal cancer. Radiother Oncol 2009, 93(2):273-278.
71. Hindler K., Cleeland C.S., Rivera E., Collard C.D. The role of statins in cancer therapy. Oncologist 2006, 11(3):306-315.
72. Bardou M., Barkun A., Martel M. Effect of statin therapy on colorectal cancer. Gut 2010, 59(11):1572-1585.
73. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352(21):2184-2192.
74. Hachem C., Morgan R., Johnson M., Kuebeler M., El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009, 104(5):1241-1248.
75. Lakha F., Theodoratou E., Farrington S.M., Tenesa A., Cetnarskyj R., Din F.V., et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 2012, 12(1):487.
76. Bonovas S., Filioussi K., Flordellis C.S., Sitaras N.M. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5million patients. J Clin Oncol 2007, 25(23):3462-3468.
77. Notarnicola M., Messa C., Pricci M., Guerra V., Altomare D.F., Montemurro S., et al. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in left-sided human colon cancer. Anticancer Res 2004, 24(6):3837-3842.
78. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999, 5(8):2223-2229.
79. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
80. Wachtershauser A., Akoglu B., Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001, 22(7):1061-1067.
81. Qi X.F., Kim D.H., Yoon Y.S., Kim S.K., Cai D.Q., Teng Y.C., et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett 2010, 199(3):277-287.
82. Skaletz-Rorowski A., Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003, 14(6):599-603.
83. Hinoue T., Weisenberger D.J., Pan F., Campan M., Kim M., Young J., et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009, 4(12):e8357.
84. Kodach L.L., Jacobs R.J., Voorneveld P.W., Wildenberg M.E., Verspaget H.W., van Wezel T., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011, 60(11):1544-1553.
85. Wang W., Collie-Duguid E., Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 2002, 531(3):415-420.
86. Riganti C., Doublier S., Costamagna C., Aldieri E., Pescarmona G., Ghigo D., et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008, 74(2):476-484.
87. Lee J., Lee I., Han B., Park J.O., Jang J., Park C., et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011, 103(8):674-688.
88. Katz M.S., Minsky B.D., Saltz L.B., Riedel E., Chessin D.B., Guillem J.G. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62(5):1363-1370.
89. Jain M.K., Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005, 4(12):977-987.
90. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6(12):1399-1402.
91. Samadder N.J., Mukherjee B., Huang S.C., Ahn J., Rennert H.S., Greenson J.K., et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 2011, 117(8):1640-1648.
92. Lee J.Y., Kim J.S., Kim J.M., Kim N., Jung H.C., Song I.S. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007, 7(2):241-248.
93. Cho S.J., Kim J.S., Kim J.M., Lee J.Y., Jung H.C., Song I.S. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123(4):951-957.
94. Suh N., Reddy B.S., DeCastro A., Paul S., Lee H.J., Smolarek A.K., et al. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) 2011, 4(11):1895-1902.
95. Banez L.L., Klink J.C., Jayachandran J., Lark A.L., Gerber L., Hamilton R.J., et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010, 19(3):722-728.
96. Malicki S., Winiarski M., Matlok M., Kostarczyk W., Guzdek A., Konturek P.C. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol 2009, 60(4):141-146.
97. Wang X.S., Williams L.A., Krishnan S., Liao Z., Liu P., Mao L., et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 2012, 26(5):699-705.
98. Coogan P.F., Smith J., Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007, 99(1):32-40.
99. Siddiqui A.A., Nazario H., Mahgoub A., Patel M., Cipher D., Spechler S.J. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009, 54(6):1307-1311.
100. Ng K., Ogino S., Meyerhardt J.A., Chan J.A., Chan A.T., Niedzwiecki D., et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011, 103(20):1540-1551.
101. Lipkin S.M., Chao E.C., Moreno V., Rozek L.S., Rennert H., Pinchev M., et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 2010, 3(5):597-603.
102. Rosuvastatin in treating patients with stage I or stage ii colon cancer that was removed by surgery 2009 [updated 09/02/2012; cited 2012 05/12/2012]. Available from: http://clinicaltrials.gov/show/NCT01011478.
103. Tønnesen H., Knigge U., Bülow S., Damm P., Fischerman K., Hesselfeldt P., et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988, 2(8618):990-992.
104. Harvey V.J., Slevin M.L., Dilloway M.R., Clark P.I., Johnston A., Lant A.F. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 1984, 18(3):421-430.
105. Adams W.J., Lawson J.A., Morris D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994, 35(11):1632-1636.
106. Cianchi F., Cortesini C., Schiavone N., Perna F., Magnelli L., Fanti E., et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005, 11(19 Pt 1):6807-6815.
107. Masini E., Fabbroni V., Giannini L., Vannacci A., Messerini L., Perna F., et al. Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res 2005, 54(Suppl. 1):S80-S81.
108. Boer K., Helinger E., Helinger A., Pocza P., Pos Z., Demeter P., et al. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol 2008, 87(4):227-236.
109. Chen J.S., Lin S.Y., Tso W.L., Yeh G.C., Lee W.S., Tseng H., et al. Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis. Mol Carcinog 2006, 45(7):461-478.
110. Matsumoto S., Imaeda Y., Umemoto S., Kobayashi K., Suzuki H., Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 2002, 86(2):161-167.
111. Siegel J.N., Schwartz A., Askenase P.W., Gershon R.K. T-cell suppression and contrasuppression induced by histamine H2 and H1 receptor agonists, respectively. Proc Natl Acad Sci USA 1982, 79(16):5052-5056.
112. Adams W.J., Morris D.L. Short-course cimetidine and survival with colorectal cancer. Lancet 1994, 344(8939-8940):1768-1769.
113. Adams W.J., Morris D.L. Pilot study-cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997, 80(1):15-21.
114. Kelly M.D., King J., Cherian M., Dwerryhouse S.J., Finlay I.G., Adams W.J., et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer 1999, 85(8):1658-1663.
115. Kapoor S., Pal S., Sahni P., Dattagupta S., Kanti Chattopadhyay T. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. J Surg Res 2005, 129(2):172-175.
116. Nielsen H.J., Moesgaard F., Hammer J.H. Effect of ranitidine and low-dose interleukin-2 in vitro on NK-cell activity in peripheral blood from patients with liver metastases from colorectal cancer. Eur J Surg Oncol 1995, 21(5):526-530.
117. Adams W.J., Morris D.L., Ross W.B., Lubowski D.Z., King D.W., Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust N Z J Surg 1994, 64(12):847-852.
118. Rasmussen L.A., Nielsen H.J., Sorensen S., Sorensen C., Rasmussen R., Moesgaard F., et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg 1995, 181(2):138-144.
119. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995, 346(8967):115.
120. Svendsen L.B., Ross C., Knigge U., Frederiksen H.J., Graversen P., Kjaergård J., et al. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 1995, 38(5):514-518.
121. Nielsen H.J., Christensen I.J., Moesgaard F., Kehlet H., Group D.R. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002, 89(11):1416-1422.
122. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138(6):2073-2087. e3.
123. Deva S., Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev 2012, 8. CD007814.
124. Galon J., Pages F., Marincola F.M., Angell H.K., Thurin M., Lugli A., et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205.